Evidence suggests women have a reduced response to nicotine replacement and other traditional treatments which is why more targeted pharmacotherapy and intervention strategies may be necessary to improve their quit rates. Opioid antagonist naltrexone is proving to be an effective adjunctive pharmacotherapy approach for female smokers.